Bedrijfsoverzicht
Kezar Life Sciences, Inc. is a clinical-stage biotechnology entity focused on the discovery and development of novel small molecule therapeutics designed to address unmet medical needs in immune-mediated diseases within the United States. The company operates within the healthcare sector, specifically the biotechnology industry, which typically involves high-risk, long-term research and development cycles before products reach commercial viability. As of the latest available data, Kezar Life Sciences, Inc. maintains a market capitalization of $54.33M and employs a workforce of nine individuals to execute its strategic initiatives. The combination of a $54.33M market cap and the absence of reported annual revenue indicates that the company is in an early-stage development phase where value is primarily derived from intellectual property potential rather than current commercial sales, reflecting a typical profile for clinical-stage biotechnology firms that are capitalizing on their pipeline rather than generating significant operating income.
Financiële gezondheid
The financial statements for Kezar Life Sciences, Inc. report net income (TTM) of $-56,033,000 and EBITDA of $-51,373,000, while revenue figures are not disclosed, indicating the company has not yet generated significant commercial sales to offset its substantial operating expenses. The gap between the reported net income and EBITDA, alongside the lack of revenue, reveals a cost structure dominated by research and development expenditures, clinical trial costs, and general administrative overheads that are currently burning through capital without corresponding sales income. The company's free cash flow stands at $-29,152,250, which signifies a negative cash position where operational outflows exceed cash inflows, necessitating ongoing capital infusion to sustain R&D activities and clinical progress. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard characteristic for pre-revenue biotechnology companies where total costs exceed total revenue, resulting in zero profitability until product commercialization occurs. In terms of balance sheet strength, Kezar Life Sciences, Inc. holds cash of $71.88M against total debt of $2.33M, resulting in a debt-to-equity ratio of 3.32, which suggests a leveraged balance sheet structure where equity is relatively small compared to debt obligations, though the high cash balance provides significant runway. The current ratio is reported at 11.52, indicating an extremely strong short-term liquidity position where current assets vastly exceed current liabilities, providing ample flexibility to meet immediate financial obligations without distress. Furthermore, the return on equity is -59.9% and the return on assets is -29.5%, metrics that reveal management is currently deploying capital to generate losses rather than profits, which is typical for clinical-stage ventures but highlights the challenge of achieving positive returns until the company transitions to revenue-generating operations.
Waarderingsbeoordeling
Valuation metrics for Kezar Life Sciences, Inc. present a unique picture due to the company's lack of earnings, with a P/E Ratio (TTM) listed as N/A and a forward P/E of -2.76, the latter implying that analysts project earnings that would result in a negative multiple if calculated based on current market conditions, or simply reflecting the absence of positive earnings growth. The price-to-book ratio is 0.77, indicating that the market values the company at 77% of its book value, which often occurs in biotechnology firms where intangible assets like intellectual property and pipeline potential are not fully captured on the balance sheet or are valued below historical cost. Since revenue is N/A, the price-to-sales ratio is also N/A, preventing a traditional sales-based valuation, while the EV/EBITDA stands at 0.30, a very low multiple that typically reflects high growth expectations or significant operational losses that depress the earnings-based valuation multiple. The stock's trading range over the last 52 weeks spans from a low of $3.53 to a high of $7.55, placing the current valuation context within this volatility band where the stock price fluctuates significantly based on clinical trial results and pipeline milestones. The beta of 0.43 indicates that the stock exhibits lower volatility relative to the broader market, moving less than half as much as the market index on average, which provides a distinct risk profile compared to high-beta equities often found in the biotechnology sector.
Growth & Income
Growth metrics for Kezar Life Sciences, Inc. show revenue growth (YoY) as N/A and earnings growth (YoY) as N/A, reflecting the company's pre-commercial stage where historical growth rates cannot be calculated due to the absence of established revenue streams. Because the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, it operates under a strategy where all available cash and earnings are reinvested into research, development, and clinical trials rather than being distributed to shareholders. The lack of a payout ratio confirms that the company retains its cash reserves to fund its nine employees and ongoing scientific operations, prioritizing long-term asset building over short-term income distribution. The overall growth and income profile is characterized by a complete focus on capital appreciation potential through future product approvals, as the company currently offers no income yield and relies entirely on successful clinical outcomes to unlock value for its shareholders.